Compare Organon & Co. Common Stock (OGN) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Oatly Group AB - ADR — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Oatly Group AB - ADR trades at $11.1 (market cap $347.84M). The key difference: Organon & Co. Common Stock is far larger — about 10.4× Oatly Group AB - ADR's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Oatly Group AB - ADR for 18 Days on average.
| OGN | OTLY | |
|---|---|---|
Market Cap | $3.62B | $347.84M |
Volume | 2,892,999 | 116,933 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $15.91 |
52-Week Low | $5.70 | $8.03 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.04B | $852.26M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
